These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38262797)

  • 21. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
    Hanžel J; D'Haens GR
    Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
    [No Abstract]   [Full Text] [Related]  

  • 22. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.
    Belvis Jiménez M; Maldonado Pérez B; Argüelles-Arias F
    J Crohns Colitis; 2018 Aug; 12(9):1134-1135. PubMed ID: 29788419
    [No Abstract]   [Full Text] [Related]  

  • 25. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Kim JH; Cheon JH
    Gut Liver; 2016 Mar; 10(2):162-3. PubMed ID: 26934881
    [No Abstract]   [Full Text] [Related]  

  • 26. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
    de Freitas LF; Feitosa MR; Féres O; Parra RS
    Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
    [No Abstract]   [Full Text] [Related]  

  • 27. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Hendy P; Hart A
    Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
    [No Abstract]   [Full Text] [Related]  

  • 28. Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.
    Wiskin AE; Paul SP; Spray CH
    Acta Paediatr; 2019 Jul; 108(7):1359-1360. PubMed ID: 30788859
    [No Abstract]   [Full Text] [Related]  

  • 29. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab for the treatment of ulcerative colitis.
    Rietdijk ST; D'Haens GR
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
    Hinojosa Del Val J; Barreiro-de Acosta M
    Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation.
    Sugimoto K; Fujita S; Miyazu T; Ishida N; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Furuta T; Osawa S
    Inflamm Bowel Dis; 2021 Jan; 27(1):e3-e4. PubMed ID: 32812020
    [No Abstract]   [Full Text] [Related]  

  • 33. Ulcerative Colitis in Adults.
    Glick LR; Cifu AS; Feld L
    JAMA; 2020 Sep; 324(12):1205-1206. PubMed ID: 32857108
    [No Abstract]   [Full Text] [Related]  

  • 34. Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Agrawal M; Verstockt B
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):2-4. PubMed ID: 34798035
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
    Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
    AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab.
    Armuzzi A; Pugliese D; Nardone OM; Guidi L
    Drug Des Devel Ther; 2013; 7():289-96. PubMed ID: 23630414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
    Chang HC; Gau SY
    Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1242. PubMed ID: 37986597
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis.
    Busquets D; Aldeguer X
    J Crohns Colitis; 2013 Jun; 7(5):e195. PubMed ID: 23219261
    [No Abstract]   [Full Text] [Related]  

  • 40. Current and emerging biologics for ulcerative colitis.
    Park SC; Jeen YT
    Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.